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ABSTRACT 
Novel Inhibitors/Inactivators of Cysteine Proteases. (May 2015) 
 
Charis Fernandez 
Department of Biochemistry and Biophysics 
Texas A&M University 
 
Research Advisor: Dr. Thomas Meek 
Department of Biochemistry and Biophysics 
 
When operating aberrantly, enzymes contribute to the mechanisms of many different diseases, 
and as such, have proven to be promising targets for the discovery of new drugs. Proteases 
catalyze the hydrolysis of peptide bonds and proteins, the result of which is the inactivation or 
de-activation of physiological processes that are often contributory to disease. The cysteine 
proteases are also involved in pathogenesis including cancer, autosomal disorders, pulmonary 
disorders, and their action assists in the infectivity of the pathogenic protozoa that cause 
Chagas’s disease and malaria. Despite their importance as therapeutic targets, currently no 
inhibitors of cysteine proteases have proven viable as treatments for these diseases. While 
numerous inhibitors of cysteine proteases exist, most of which inactivate these enzymes by 
covalent reaction, none have to date proven sufficiently specific to serve as drugs. We are 
beginning to develop novel types of covalent inactivators, which utilize detailed aspects of the 
mechanism and structure of cysteine proteases to render them highly selective toward their 
targets. The cysteine proteases human cathepsin C and cathepsin L were used as models to 
develop new inhibitors because they are available, well characterized kinetically, and the 
structure of human cathepsin C has been fully determined. This model served as a means to apply 
the same chemistry or similar to other enzymes such as falcipain-2, a drug target for malaria. Falcipain-2 
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was prepared as a recombinant protein. Three compounds, Cbz-Phe-Phe-CHO, Cbz-Phe-Phe-
vinyl-phenylsulfone (Cbz-Phe-Phe-VSPh), and Cbz-Phe-Phe-2-vinylpyrimidine (Cbz-Phe-Phe-
2VP), were shown to be time-dependent inhibitors/inactivators of falcipain-2 with apparent 
values of Ki = 0.25 nM, 32 nM, and 70 nM, respectively. Cbz-Phe-Phe-VSPh was a clinical 
candidate for treatment of malaria, but failed because it lacked sufficient specificity for falcipain-
2. It does serve, however, as a “benchmark” inactivator for comparison with our novel 
inactivator Cbz-Phe-Phe-2VP. This inactivator has a pyrimidine ring that allows for “tuning” of 
its electrophilicity to create different levels of specificity. An increase in specificity for falcipain-
2 could result in a decrease in side effects and more targeted clinical applications for treatment of 
malaria.  
  
3	  
	  
ACKNOWLEDGMENTS 
 
I would like to thank Dr. Tom Meek for his support and guidance putting together this thesis. I 
have learned a lot from him as a student and a person, and I could not be more thankful for the 
opportunity to work with him in his lab. I would also like to thank Dr. Bala Chenna, Dr. 
Stephanie Perez, Dr. Xiang Zhai, Dat Truong, and Jennifer Julizar with their help synthesizing 
our compounds, expressing our enzymes, and working on the enzyme kinetics.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
4	  
	  
NOMENCLATURE 
 
Cbz – carbobenzoxy, a protecting group 
AMC – 7-amino-4-methyl-coumarin 
VSPh – vinyl-phenylsulfone 
2VP – 2-vinyl-pyrimidine 
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CHAPTER I 
INTRODUCTION 
 
Many different diseases arise from the aberrant activities of enzymes that otherwise govern 
normal metabolic processes. Because of this important role, enzymes are excellent targets for 
drugs. Cathepsin C, cruzain, and falcipain, all part of the papain clan of the cysteine protease 
enzyme family, are involved in prevalent diseases and comprise validated targets for drug 
development. Cathepsin C is a target for cystic fibrosis treatment among other respiratory 
disorders, cruzain is critical for the life cycle of Trypanosoma cruzi – the causative agent of 
Chagas’s disease, and falcipain-2 is critical for the life cycle of Plasmodium falciparum – the 
causative agent of malaria. Various covalent inhibitors of these enzymes have been developed 
including epoxides, peptidic aldehydes, α-halo-ketones, nitriles, and vinyl-sulfones.  However, 
these electrophilic groups in general have proven to be too reactive or non-specific to achieve the 
necessary selectivity required for progression to therapeutic use. Cathepsin C is an ideal model 
with which to begin exploring new covalent agents because it is so well characterized, and its 
substrates are simple dipeptides1,2. This enzyme is also very useful in that it has a wide substrate 
specificity, so many different dipeptides can be used to create covalent inhibitors2. Additionally, 
the cysteine protease human cathepsin L is currently available, and has similar substrate 
specificity to falcipain-2, such that peptide-based inactivators of this enzyme may also be active 
against falcipain-2, and cathepsin L serves as a selectivity “marker” of inactivation. We began 
with both the H2N-Gly-Phe and the Cbz-Phe-Phe peptide templates, the former of which 
comprises one of the most active dipeptide substrates of cathepsin C as H2N-Gly-Phe-AMC2. 
The aldehyde analogues of the H2N-Gly-Phe and Cbz-Phe-Phe dipeptides, H2N-Gly-Phe-CHO 
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and Cbz-Phe-Phe-CHO, respectively, are available by four synthetic steps3, and these aldehydes 
proved useful as covalent inactivators of cathepsin C and cathepsin L/falcipain-2, given that they 
likely form a hemithioacetal with the active-site cysteines. The cysteine protease family can be 
potently inhibited/inactivated by vinyl-sulfone compounds because the thiol in the active site of 
the enzymes can perform a Michael reaction to the activated vinyl moiety, thereby becoming 
“covalently arrested” and unable to continue catalysis4. Vinyl-sulfone inhibitors have proven to 
be effective against cathepsin C, cathepsin L, as well as falcipain-2 and cruzain, and these 
compounds have been prepared from peptide aldehydes using Wittig and Horner-Wadsworth-
Emmons chemistry5,6. These vinyl inhibitors have been effective, but their reactivity with the 
cysteine residue could be better controlled if the sulfone group was replaced with other groups 
that could still elicit a Michael reaction, but could also be easily altered to produce modulatable 
electrophilicity. If the reactivity of these inhibitors could be modulated in this manner, they 
would have a greater specificity against clinically important enzymes such as cathepsin C, 
cruzain, and falcipain-2. This increased specificity would mean that the drugs could be more 
effective at targeting these enzymes, which would result in a decrease in side effects and more 
targeted clinical applications. 
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CHAPTER II 
METHODS 
 
Synthesis of Inactivators 
The inactivators used against cathepsin C, cathepsin L, and falcipain-2 were synthesized by a 
chemist in the lab. The aldehyde, Cbz-Phe-Phe-CHO, was synthesized in four synthetic steps, as 
shown in Figure 1. This aldehyde was used as a covalent inactivator of falcipain-2 by forming a 
covalent hemithioacetal with the active-site cysteine. The peptide aldehyde served two 
convenient roles: as a potent protease inactivator and as a chemical intermediate toward the final 
vinyl heterocycle product. The vinyl-pyrimidine inactivator was synthesized using the aldehyde 
by a Wittig reaction in which the aldehyde was reacted with a triphenylphosphonium ylide, as 
shown in Figure 1. The suspected mechanism of inactivation of this vinyl-pyrimidine inactivator 
(6) shown in Figure 2, in which proton transfer from His-162 in the enzyme’s active site 
activates the pyrimidine ring and vinyl group for attack by the thiolate of Cys-25, forming a 
covalent bond between the enzyme and inactivator.  
 
	  
Figure 1. Synthesis of di-peptide aldehyde and di-peptide vinyl-pyrimidine inactivators. Di-peptide aldehydes 3 
were made in three steps from the protected di-peptide carboxylic acids via formation of Weinreb amides, followed 
by reduction. Triphenylphosphonium ylides 4 were made in three steps from methyl esters of 2-carboxy-
pyrimidines, and generic di-peptide 2-vinyl-pyrimidines 5 were formed by a single step Wittig condensation of 3 
and 4.  
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Figure 2. Proposed mechanism of inactivation by Cbz-Phe-Phe-2-vinylpyrimidine (6). The vinyl-pyrimidine likely 
inactivates enzymes in this proton-assisted mechanism.  
 
Optimization of Peptide Substrates 
The catalytic efficiencies of peptide substrates of cathepsin C, cathepsin L, and falcipain-2 were 
studied. Ideal substrates were selected based on size, solubility, and kinetic parameters. A panel 
of synthetic or commercially available peptide substrates of the form X-P1-P2-C(O)-NH-AMC 
were used. These peptide substrates contained a 7-amino-4-methylcoumarin (AMC) group at the 
scissile amide bond, which becomes fluorescent upon enzyme-catalyzed hydrolysis. P1 and P2 
are naturally occurring (Phe, Arg, Leu, Val) amino acid side chains, and X is a carbobenzoxy or 
a similar substituent. We characterized the kinetic parameter Km of a few AMC containing 
peptide substrates for which the lowest values of Km comprised the substrates that are best 
recognized and hydrolyzed by cathepsin C, cathepsin L, and falcipain-2.  
 
Characterization of Inactivators 
The synthesized di-peptide-vinyl-pyrimidine, Cbz-Phe-Phe-2VP, was used to inactivate 
cathepsin L as a model for falcipain-2. The peptide-aldehyde inactivator, Cbz-Phe-Phe-CHO, a 
di-peptide-vinyl-phenylsulfone inactivator, Cbz-Phe-Phe-VSPh, and Cbz-Phe-Phe-2VP were 
used to inactivate falcipain-2. A time-dependent, tight-binding inhibition evaluation was 
performed in which enzyme and inhibitor were allowed to incubate for 30-60 minutes, followed 
by addition of substrate to initiate the reaction. The hydrolysis of the AMC group on the 
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substrate used, Cbz-Phe-Arg-AMC, produced fluorescence in the 360-460 nm range and a 
corresponding time course of the enzymatic reaction. The fluorescent intensity was measured 
and corresponded to thenzyme activity. As the enzyme and inhibitor associate, they form the 
complex EI, as shown in Figure 3. The EI complex is established quickly, in a matter of 
 
 
milliseconds. The EI* complex formed from the EI complex is the tight-binding complex, and is 
established over the course of a few minutes. The kinetic parameter, Ki*, was determined for 
each of the inactivators according to the equation shown in Figure 3. This parameter is indicative 
of how potent the inhibitor is as a measure of the concentration of inhibitor required to produce 
half maximum inhibition. Thus, a smaller Ki* value corresponds to a more potent inhibitor.  
 
 
 
 
 
 
 
 
 
Figure 3. Time-dependent tight-binding inhibition 
E  +  I  EI                   EI*
k1
k2
Ki = k2/k1
k3 
k4
Ki* = (k2/k1)(k4/(k3 + k4))
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CHAPTER III 
RESULTS 
 
Optimization of Peptide Substrates 
Kinetic parameters of peptide substrates were characterized for cathepsin C, cathepsin L, and 
falcipain-2 for those substrates that were most efficient and best recognized by their respective 
enzymes. The best substrate for cathepsin C was determined to be H2N-Gly-Phe-AMC2. The best 
substrate for both cathepsin L and falcipain-2 was determined to be Cbz-Phe-Arg-AMC. The 
Michaelis-Menten model was used to calculate the Km for each enzyme and substrate, as shown 
in Table I.  
 
Table I. The Km values for cathepsin C, cathepsin L, and falcipain-2 and their respective substrates 
Enzyme Substrate Km 
cathepsin C H2N-Gly-Phe-AMC 75 µM ±15 
cathepsin L Cbz-Phe-Phe-AMC 20 µM 
falcipain-2 Cbz-Phe-Phe-AMC 13 µM ±2 
 
Characterization of Inactivators 
Characterization of Cbz-Phe-Phe-CHO 
The inactivator Cbz-Phe-Phe-CHO was used to inactivate falcipain-2. A time-dependent, tight-
binding inhibition evaluation was run in which 25 nM falcipain-2 was mixed with Cbz-Phe-Phe-
CHO, and the reaction mixture was allowed to pre-incubate for 30 minutes before addition of 
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100 µM Cbz-Phe-Arg-AMC as the substrate to initiate the reaction. The tight-binding inhibition 
time course is shown in Figure 5. As the concentration of Cbz-Phe-Phe-CHO increased, the rate  
 
 
of falcipain-2 activity decreased, following a time course that was characteristic of tight-binding  
inhibition and shown to be extremely potent. The Ki* was calculated from fitting of the data to 
the equation shown in Figure 5 using SigmaPlot to be 250 ± 10 pM.  
 
Figure 5. Tight-binding inhibition equation in which Pt is equal to the AMC formed at time t, vs and vi are the 
steady-state and initial velocities of the cysteine protease, and kobs is the apparent rate of conversion of EI to EI* at a 
given concentration of inhibitor (I).  
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Figure 4. Tight-binding inhibition time course shows inhibition of falcipain-2 by Cbz-
Phe-Phe-CHO. Falcipain-2 activity decreases as concentration of Cbz-Phe-Phe-CHO 
increases. 
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Characterization of Cbz-Phe-Phe-VSPh 
The inactivator Cbz-Phe-Phe-VSPh was used to inactivate falcipain-2. A time-dependent, tight-
binding inhibition evaluation was run in which 130 nM falcipain-2 was mixed with Cbz-Phe-
Phe-VSPh, and the reaction mixture was allowed to pre-incubate for 60 minutes before addition 
of 50 µM Cbz-Phe-Arg-AMC as the substrate to initiate the reaction. The tight-binding inhibition 
time course is shown in Figure 6. As the concentration of Cbz-Phe-Phe-VSPh increased, the rate  
 
 
of falcipain-2 activity decreased. The Ki* was calculated from fitting of the data to the equation 
shown in Figure 5 using SigmaPlot to be 32 ± 1 nM.  
 
Characterization of Cbz-Phe-Phe-2VP 
The novel inactivator Cbz-Phe-Phe-2VP was first used to inactivate cathepsin L as a model for 
falcipain-2. A time-dependent, tight-binding evaluation was run in which cathepsin L was mixed 
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Figure 6. Tight-binding inhibition time course shows inhibition of falcipain-2 by Cbz-Phe-Phe-VSPh. Falcipain-2 
activity decreases as concentration of Cbz-Phe-Phe-VSPh increases. 
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with Cbz-Phe-Phe-2VP, and the reaction mixture was allowed to pre-incubate for 60 minutes 
before addition of 20 µM Cbz-Phe-Arg-AMC as the substrate to initiate the reaction. As the 
concentration of Cbz-Phe-Phe-2VP is increased, the rate of cathepsin L decreased. The vinyl-
pyrimidine inhibitor was an apparent competitive inhibitor of cathepsin L. The Ki* value was 
calculated from fitting of the data to the equation shown in Figure 5 using SigmaPlot to be 1.0 ± 
0.1 µM.	   
 
The novel inactivator Cbz-Phe-Phe-2VP was used to inactivate falcipain-2. A time-dependent, 
tight-binding inhibition evaluation was run in which 130 nM falcipain-2 was mixed with Cbz-
Phe-Phe-2VP, and the reaction mixture was allowed to pre-incubate for 60 minutes before 
addition of 50 µM Cbz-Phe-Arg-AMC as the substrate to initiate the reaction. The tight-binding 
inhibition time course is shown in Figure 7. As the concentration of Cbz-Phe-Phe-2VP  
increased, the rate of falcipain-2 activity decreased. The Ki* was calculated using SigmaPlot and 
the equation in Figure 3 to be 70 ± 20 nM. 
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Figure 7. Tight-binding inhibition time course shows inhibition of falcipain-2 by Cbz-Phe-Phe-2VP. 
Falcipain-2 activity decreases as concentration of Cbz-Phe-Phe-2VP increases. 
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CHAPTER IV 
CONCLUSIONS 
 
The inactivators that we synthesized all effectively inhibited falcipain-2, some demonstrating 
tight-binding inhibition/inactivation. The Ki* values that we determined in the time-dependent 
tight-binding inhibition reactions are shown in Table II. The most potent inactivator, Cbz-Phe-
Phe-CHO, is likely to be too non-specific to be a potential drug candidate,  
 
Table II. Inhibition Constant Ki* values describing the inhibition of enzyme with each inactivator 
Inactivator Enzyme Inhibition Constant Ki* 5 
Cbz-Phe-Phe-CHO falcipain-2 0.25 ± 0.01 
Cbz-Phe-Phe-VSPh falcipain-2 32 ± 1 
Cbz-Phe-Phe-2VP 
cathepsin L 2950 
falcipain-2 70 ± 20 
 
although its inhibition constant indicates very tight-binding. The next most potent inactivator, 
Cbz-Phe-Phe-VSPh, achieved Phase I clinical trials to use as an inhibitor against falcipain-2 for 
the treatment of malaria. It failed, however, because it was not specific enough against falcipain. 
Our novel inactivator, Cbz-Phe-Phe-2VP, did not bind as tightly to falcipain-2 as Cbz-Phe-Phe-
CHO and Cbz-Phe-Phe-2VP, but it still effectively inhibited it with apparent tight-binding 
inhibition. When compared to its inhibition of cathepsin L, the Cbz-Phe-Phe-2VP inhibition of 
falcipain-2 was much more potent. This suggests that our novel inactivator has some level of 
specificity for falcipain-2 as opposed to other enzymes even when compared to its interactions 
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with those that have similar substrate specificities, such as cathepsin L. The next steps toward 
creating a potential drug candidate for malaria by targeting falcipain-2 are to further characterize 
our compound and to compare its inhibition of falcipain-2 to that of other enzymes in the 
cysteine protease family. This will help us better understand its specificity for falcipain-2, which 
in turn could lead to a more effective drug candidate. Substitution of the pyrimidine ring on the 
novel inactivator, Cbz-Phe-Phe-2VP, with electron-donating and electron-withdrawing groups 
will allow for “tuning” of the electrophilicity of the vinyl “warhead” of the peptidomimetic 
inhibitor. This change in electrophilicity will change the ability of the compound to react with 
specific enzymes. With the flexibility that this gives us, a compound that is both potent and 
specific against the malarial enzyme falcipain-2 will likely be seen in the near future.   
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